Practical
What to Do in a GLP-1 Shortage
Supply gaps are not an edge case in this drug class, they are a recurring feature. The damage is rarely the missed weeks themselves — it is what people do on either side of them.
Shortages in this class have been recurrent rather than exceptional, and they are as likely to be caused by demand, manufacturing capacity or an insurance formulary change as by anything dramatic.
The pattern I see is consistent: the missed weeks themselves are rarely the problem. The problem is what people do on either side of them.
Before you run out: the call to make
The useful options nearly all require a prescription, which means the time to act is when you have 2–3 weeks of supply left, not on the day the pharmacy says no.
Ask your prescriber:
- Is there a different brand of the same molecule available? Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. Availability often differs between them, and moving is a relatively simple mapping.
- Is a different dose strength or format in stock? Sometimes the shortage is one strength.
- Should I switch molecule? A real option, and it resets your titration — the mechanics are in switching between GLP-1 medications.
- If I have to pause, what is the restart plan? Get this in writing, with doses for 2, 4 and 8 weeks off.
That last question is the one almost nobody asks and the one that prevents the most harm.
Do not stretch doses on your own
The intuition is reasonable: take it every 10 days instead of 7 and the supply lasts longer. The pharmacology does not cooperate.
These are weekly drugs dosed at roughly their own half-life, so each dose lands on what remains of the last one and the concentration reaches a steady state. Lengthening the interval lowers your average concentration — you do not get the same effect spread thinner, you get less effect. The accumulation arithmetic is in how long GLP-1s stay in your system.
There is a device hazard too. Dialling partial doses, or drawing from a pen with a separate syringe, is outside how these products were designed and tested, and it is a well-recognised route to dosing errors.
If supply is genuinely short, a planned lower dose agreed with your prescriber is a better answer than an improvised schedule — same reduction in consumption, without the guesswork.
The restart, which is where people get hurt
This is the most important section here.
Tolerance to the gastrointestinal effects fades, and faster than people expect. Restarting 2.4 mg of semaglutide or 15 mg of tirzepatide after a month away can produce the side effects of a first injection at a dose four or five steps up the ladder — genuinely severe nausea and vomiting, in someone who felt fine on that dose in March.
Rough shape, and your prescriber’s version governs:
| Time off | Usual approach |
|---|---|
| 1 missed dose | Resume as normal |
| 2–3 missed doses | Often one step down; ask |
| More than about 4 weeks | Expect to re-titrate, often from low |
Labelling for some products advises considering reinitiation at a lower dose after as few as two missed weekly doses. The full rescue-window detail is in what to do if you miss a dose.
What happens during the gap, and what it means
Appetite returns, often abruptly, within a few weeks. Some weight comes back. This is expected.
The STEP 1 extension found participants regained a substantial share of lost weight within a year of stopping, along with much of the cardiometabolic improvement. That is pharmacology, not a verdict on you — the full argument is in what happens when you stop.
Practically, during a gap:
- Hold the protein target. It is the thing most worth defending, because lean mass lost is slow to rebuild. What to actually eat.
- Keep lifting. Twice a week protects what you have.
- Do not compensate by restricting. A hard diet on top of returning appetite tends to end badly and costs muscle.
- Expect it to be psychologically hard. The return of food noise after months of quiet is a real experience and people are unprepared for it — food noise, mood, and the quiet months.
Where compounded products fit
Compounding permissions in the United States are tied to formal shortage status, which changes as supply resolves, so the legal picture moves.
What does not move: compounded products are not FDA-approved, potency and purity vary by facility, and the FDA has published safety communications about them — including dosing errors from vials and syringes, and salt forms that are not the molecule studied in the trials.
If you use one, do it under a clinician who knows, and apply one rule without exception: know your dose in milligrams. Not in units, not in fractions of a syringe. Instructions given in units are the highest-risk pattern in this market and have caused real overdoses. That test, and the others worth applying to a provider, are in how to choose a GLP-1 prescriber.
Two situations that need urgency
Type 2 diabetes. A gap is a glycemic control problem, not only a weight problem, and it may need other medication adjusted in the interim. Call rather than wait.
Do not buy from unverified sources. Not social media, not a peer, not a website with no named prescriber. Counterfeit GLP-1 products have been identified in multiple markets, and you cannot assess what is in a vial by looking at it.
The one thing to do today
Ask your prescriber for a written restart plan — which dose to resume at after 2, 4 and 8 weeks off — and keep it with your prescription.
It takes one message, it costs nothing, and it is the difference between a supply gap being an inconvenience and being the fortnight you felt worse than at any point in your treatment.
Questions I get about this month
- What should I do if I cannot get my GLP-1?
- Contact your prescriber before you run out rather than after, because the useful options mostly need a prescription. They may include switching to a different brand of the same molecule, switching molecule, changing pharmacy or dispensing format, or agreeing a planned pause with a defined restart. What you should not do is quietly ration what you have or source it from an unverified supplier. The gap itself is manageable; improvising through it is where the harm comes from.
- Can I stretch my doses to make my supply last longer?
- It is not a free workaround and it deserves an explicit conversation rather than a private decision. Taking a weekly drug every 10 days lowers your average blood concentration, so the likely result is reduced effect rather than the same effect for longer. With a multi-dose pen there is also a practical hazard: dialling partial doses or drawing from a pen with a syringe introduces dosing errors, and it is outside how the device was designed and tested. If supply is short, your prescriber may prefer a planned lower dose to an improvised schedule.
- How do I restart a GLP-1 after being off it for a month?
- Usually at a lower dose than you stopped at, and this is the single most important thing in this article. Tolerance to the gastrointestinal effects fades within weeks, so resuming 2.4 mg or 15 mg after a month away can produce the side effects of a first injection at a dose several steps up the ladder. Labelling for some products advises considering reinitiation at a lower dose after as little as two missed weekly doses. Get the restart dose from your prescriber rather than assuming.
- Is it safe to use compounded semaglutide during a shortage?
- Compounded products are not FDA-approved, and the agency has published safety communications about them, including dosing errors from vials and syringes and salt forms that are not the studied molecule. Compounding permissions in the United States are tied to formal shortage status, which changes over time, so the legal position moves. If you use one, do it under a clinician who knows, and insist on knowing your dose in milligrams rather than in syringe units or fractions.
Sources
- 01FDA. Medicines containing semaglutide marketed for type 2 diabetes or weight loss — safety information on compounded products.
- 02FDA prescribing information, Wegovy (semaglutide) injection.
- 03FDA prescribing information, Mounjaro (tirzepatide) injection.
- 04Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism, 2022.
- 05Overgaard RV et al. Clinical Pharmacokinetics of Semaglutide. Clinical Pharmacokinetics, 2019.
Elise Hall, MD
Board-certified internist in Los Angeles, twenty-one years in practice. She writes about GLP-1 medications and metabolic health for people who want the reasoning, not just the conclusion — and publishes her own year on one of these drugs alongside it.
Keep reading
Supplements
The Best Supplements for GLP-1 Hair Loss
The shedding starts two to four months after the loss speeds up, which is why almost nobody connects the two. Seven supplements ranked — and one of them interferes with the blood test that rules out a heart attack.
Supplements
Best Bone Health Supplements on a GLP-1
Bone is the tissue nobody thinks about until a wrist breaks. Rapid weight loss reduces bone mineral density, the effect is largest in exactly the people most likely to be prescribed these drugs, and none of it produces a symptom until it does.
Tools
The Best GLP-1 Apps, Ranked
I scored every tracker I could get my hands on against seven criteria that matter specifically on a GLP-1 — not generic calorie counting. Here is the ranking, the rubric behind it, and where my first choice falls short.